TY - JOUR
T1 - TRIM28 haploinsufficiency predisposes to Wilms tumor
AU - Diets, Illja J.
AU - Hoyer, Juliane
AU - Ekici, Arif B.
AU - Popp, Bernt
AU - Hoogerbrugge, Nicoline
AU - van Reijmersdal, Simon V.
AU - Bhaskaran, Rajith
AU - Hadjihannas, Michel
AU - Vasileiou, Georgia
AU - Thiel, Christian T.
AU - Seven, Didem
AU - Uebe, Steffen
AU - Ilencikova, Denisa
AU - Waanders, Esmé
AU - Mavinkurve-Groothuis, Annelies M.C.
AU - Roeleveld, Nel
AU - de Krijger, Ronald R.
AU - Wegert, Jenny
AU - Graf, Norbert
AU - Vokuhl, Christian
AU - Agaimy, Abbas
AU - Gessler, Manfred
AU - Reis, André
AU - Kuiper, Roland P.
AU - Jongmans, Marjolijn C.J.
AU - Metzler, Markus
N1 - Funding Information:
We thank the Genome Technology Center Nijmegen. We thank Sabrina Bausenwein, Heike Streitenberger and Barbara Ziegler for expert technical assistance in the Wilms tumor biobank, and Christa Winkelmann for support in preparation of IHC specimens. We thank Daniela Schweitzer and Olga Zwenger for their technical assistance. Illja J. Diets is funded by The KiKa Foundation (project 127). Esmé Waanders was funded by the Dutch Cancer Society (KUN2012-5366). The funding agencies did not have influence on the generation and publication of the data.
Funding Information:
Illja J. Diets is funded by The KiKa Foundation (project 127). Esmé Waan-ders was funded by the Dutch Cancer Society (KUN2012-5366). The funding agencies did not have influence on the generation and publication of the data.
Publisher Copyright:
© 2019 UICC
PY - 2019/8/15
Y1 - 2019/8/15
N2 - Two percent of patients with Wilms tumors have a positive family history. In many of these cases the genetic cause remains unresolved. By applying germline exome sequencing in two families with two affected individuals with Wilms tumors, we identified truncating mutations in TRIM28. Subsequent mutational screening of germline and tumor DNA of 269 children affected by Wilms tumor was performed, and revealed seven additional individuals with germline truncating mutations, and one individual with a somatic truncating mutation in TRIM28. TRIM28 encodes a complex scaffold protein involved in many different processes, including gene silencing, DNA repair and maintenance of genomic integrity. Expression studies on mRNA and protein level showed reduction of TRIM28, confirming a loss-of-function effect of the mutations identified. The tumors showed an epithelial-type histology that stained negative for TRIM28 by immunohistochemistry. The tumors were bilateral in six patients, and 10/11 tumors are accompanied by perilobar nephrogenic rests. Exome sequencing on eight tumor DNA samples from six individuals showed loss-of-heterozygosity (LOH) of the TRIM28-locus by mitotic recombination in seven tumors, suggesting that TRIM28 functions as a tumor suppressor gene in Wilms tumor development. Additionally, the tumors showed very few mutations in known Wilms tumor driver genes, suggesting that loss of TRIM28 is the main driver of tumorigenesis. In conclusion, we identified heterozygous germline truncating mutations in TRIM28 in 11 children with mainly epithelial-type Wilms tumors, which become homozygous in tumor tissue. These data establish TRIM28 as a novel Wilms tumor predisposition gene, acting as a tumor suppressor gene by LOH.
AB - Two percent of patients with Wilms tumors have a positive family history. In many of these cases the genetic cause remains unresolved. By applying germline exome sequencing in two families with two affected individuals with Wilms tumors, we identified truncating mutations in TRIM28. Subsequent mutational screening of germline and tumor DNA of 269 children affected by Wilms tumor was performed, and revealed seven additional individuals with germline truncating mutations, and one individual with a somatic truncating mutation in TRIM28. TRIM28 encodes a complex scaffold protein involved in many different processes, including gene silencing, DNA repair and maintenance of genomic integrity. Expression studies on mRNA and protein level showed reduction of TRIM28, confirming a loss-of-function effect of the mutations identified. The tumors showed an epithelial-type histology that stained negative for TRIM28 by immunohistochemistry. The tumors were bilateral in six patients, and 10/11 tumors are accompanied by perilobar nephrogenic rests. Exome sequencing on eight tumor DNA samples from six individuals showed loss-of-heterozygosity (LOH) of the TRIM28-locus by mitotic recombination in seven tumors, suggesting that TRIM28 functions as a tumor suppressor gene in Wilms tumor development. Additionally, the tumors showed very few mutations in known Wilms tumor driver genes, suggesting that loss of TRIM28 is the main driver of tumorigenesis. In conclusion, we identified heterozygous germline truncating mutations in TRIM28 in 11 children with mainly epithelial-type Wilms tumors, which become homozygous in tumor tissue. These data establish TRIM28 as a novel Wilms tumor predisposition gene, acting as a tumor suppressor gene by LOH.
KW - genetic predisposition
KW - haploinsufficiency
KW - TRIM28
KW - Wilms tumor
KW - Loss of Heterozygosity/genetics
KW - Humans
KW - Child, Preschool
KW - Genetic Predisposition to Disease/genetics
KW - Genotype
KW - Infant
KW - Male
KW - Loss of Function Mutation/genetics
KW - Haploinsufficiency/genetics
KW - Wilms Tumor/genetics
KW - Whole Exome Sequencing/methods
KW - DNA, Neoplasm/genetics
KW - Kidney Neoplasms/genetics
KW - Female
KW - Germ-Line Mutation/genetics
KW - Heterozygote
KW - Genes, Wilms Tumor/physiology
KW - Tripartite Motif-Containing Protein 28/genetics
KW - Carcinogenesis/genetics
UR - https://www.scopus.com/pages/publications/85061566126
U2 - 10.1002/ijc.32167
DO - 10.1002/ijc.32167
M3 - Article
C2 - 30694527
SN - 0020-7136
VL - 145
SP - 941
EP - 951
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 4
ER -